Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership ...

Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...

NTLA is planning to prioritize the development of its late-stage programs — NTLA-2002 and nexiguran ziclumeran (nex-z). The company will also reduce its workforce by 27% in 2025. Nexiguran ...